-
Taiwan police rule out 'terrorism' in metro stabbing
-
Australia falls silent, lights candles for Bondi Beach shooting victims
-
DR Congo's amputees bear scars of years of conflict
-
Venison butts beef off menus at UK venues
-
Cummins, Lyon doubts for Melbourne after 'hugely satsfying' Ashes
-
West Indies 43-0, need 419 more to win after Conway joins elite
-
'It sucks': Stokes vows England will bounce back after losing Ashes
-
Australia probes security services after Bondi Beach attack
-
West Indies need 462 to win after Conway's historic century
-
Thai border clashes displace over half a million in Cambodia
-
Australia beat England by 82 runs to win third Test and retain Ashes
-
China's rare earths El Dorado gives strategic edge
-
Japan footballer 'King Kazu' to play on at the age of 58
-
New Zealand's Conway joins elite club with century, double ton in same Test
-
Australian PM orders police, intelligence review after Bondi attack
-
Durant shines as Rockets avenge Nuggets loss
-
Pressure on Morocco to deliver as Africa Cup of Nations kicks off
-
Australia remove Smith as England still need 126 to keep Ashes alive
-
Myanmar mystics divine future after ill-augured election
-
From the Andes to Darfur: Colombians lured to Sudan's killing fields
-
Eagles win division as Commanders clash descends into brawl
-
US again seizes oil tanker off coast of Venezuela
-
New Zealand 35-0, lead by 190, after racing through West Indies tail
-
West Indies 420 all out to trail New Zealand by 155
-
Arteta tells leaders Arsenal to 'learn' while winning
-
Honour to match idol Ronaldo's Real Madrid calendar year goal record: Mbappe
-
Dupont helps Toulouse bounce back in Top 14 after turbulent week
-
Mbappe matches Ronaldo record as Real Madrid beat Sevilla
-
Gyokeres ends drought to gift Arsenal top spot for Christmas
-
Arsenal stay top despite Man City win, Liverpool beat nine-man Spurs
-
US intercepts oil tanker off coast of Venezuela
-
PSG cruise past fifth-tier Fontenay in French Cup
-
Isak injury leaves Slot counting cost of Liverpool win at Spurs
-
Juve beat Roma to close in on Serie A leaders Inter
-
US intercepts oil tanker off coast of Venezuela: US media
-
Zelensky says US must pile pressure on Russia to end war
-
Haaland sends Man City top, Liverpool beat nine-man Spurs
-
Epstein victims, lawmakers criticize partial release and redactions
-
Leverkusen beat Leipzig to move third in Bundesliga
-
Lakers guard Smart fined $35,000 for swearing at refs
-
Liverpool sink nine-man Spurs but Isak limps off after rare goal
-
Guardiola urges Man City to 'improve' after dispatching West Ham
-
Syria monitor says US strikes killed at least five IS members
-
Australia stops in silence for Bondi Beach shooting victims
-
Olympic champion Joseph helps Perpignan to first Top 14 win despite red card
-
Zelensky says US mooted direct Ukraine-Russia talks on ending war
-
Wheelchair user flies into space, a first
-
Brazil's Lula, Argentina's Milei clash over Venezuela at Mercosur summit
-
Haaland sends Man City top, Chelsea fightback frustrates Newcastle
-
Thailand on top at SEA Games clouded by border conflict
Treatment improves cognition in Down Syndrome patients
A new hormone treatment improved the cognitive function of six men with Down Syndrome by 10-30 percent, scientists said Thursday, adding the "promising" results may raise hopes of improving patients' quality of life.
However the scientists emphasised the small study did not point towards a cure for the cognitive disorders of people with Down Syndrome and that far more research is needed.
"The experiment is very satisfactory, even if we remain cautious," said Nelly Pitteloud of Switzerland's Lausanne University Hospital and co-author of a new study in the journal Science.
Down Syndrome is the most common genetic form of intellectual disability, occurring in around one in 1,000 people, according to the World Health Organization.
Yet previous research has failed to significantly improve cognition when applied to people with the condition, which is why the latest findings are "particularly important", the study said.
Recent discoveries have suggested that how the gonadotropin-releasing hormone (GnRH) is produced in the brain can affect cognitive functioning such as memory, language and learning.
GnRH hormones regulate how much testosterone and estrogen is produced and increased levels of it help spur puberty.
"We wondered if this hormone could play any role in establishing the symptoms of people with Down Syndrome," said Vincent Prevot, study co-author and head of neuroscience research at France's INSERM institute.
- Mice research -
The team first established that five strands of microRNA regulating the production of GnRH were dysfunctional in mice specifically engineered for Down Syndrome research.
They then demonstrated that cognitive deficiencies -- as well as loss of smell, a common symptom of Down Syndrome -- were linked to dysfunctioning GnRH secretion in the mice.
The team then gave the mice a GnRH medication used to treat low testosterone and delayed puberty in humans, finding that it restored some cognitive function and sense of smell.
A pilot study was conducted in Switzerland involving seven men with Down Syndrome aged 20 to 50.
They each received the treatment through their arm every two hours over a period of six months, with the drug delivered in pulses to mimic the hormone's frequency in people without Down Syndrome.
Cognition and smell tests were carried out during the treatment, as were MRI scans.
Six of the seven men showed improvement in cognition with no significant side effects -- however none showed a change in their sense of smell.
"We have seen an improvement of between 10-30 percent in cognitive functions, in particular with visuospatial function, three-dimensional representation, understanding of instructions as well as attention," Pitteloud said.
The patients were asked to draw a simple 3D bed at several stages throughout the therapy. Many struggled at the beginning but by the end the efforts were noticeably better.
- 'Improve quality of life' -
The authors acknowledged some limitations of the study, including its size and that the choice of patients was "pushed by their parents".
"The clinical trial only focused on seven male patients -- we still have a lot of work to do to prove the effectiveness of GnRH treatment for Down Syndrome," Pitteloud said.
A larger study involving a placebo and 50 to 60 patients, a third of them women, is expected to begin in the coming months.
"We are not going to cure the cognitive disorders of people with Down Syndrome, but the improvement seen in our results already seems fundamental enough to hope to improve their quality of life," Pitteloud said.
Fabian Fernandez, an expert in cognition and Down Syndrome at the University of Arizona who was not involved in the research, hailed the "tour de force study".
He told AFP that while it is "difficult to envision" how such an intensive treatment could be used for young people, it might be better suited to delay the Alzheimer's disease-related dementia suffered by many adults with Down Syndrome.
It was also difficult to predict how such an improvement could impact the lives of people with the condition, he said.
"For some, it could be significant, however, as it would enable them to be more independent with daily living activities such as maintaining and enjoying hobbies, finding belongings, using appliances in the home, and travelling alone."
P.A.Mendoza--AT